Adhering to Endocrine Therapy Is Hard. What Can Be Done? Adhering to Endocrine Therapy Is Hard. What Can Be Done?
Poor adherence to adjuvant endocrine therapy remains an issue among patients with breast cancer. What can oncologists and patients do to improve long-term use?Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - September 25, 2023 Category: Drugs & Pharmacology Tags: Hematology-Oncology News Source Type: news
Interventions Can Increase Adjuvant Endocrine Treatment Adherence
THURSDAY, Sept. 14, 2023 -- Lowering medication costs and some psychosocial and reminder interventions show the most promise for promoting adjuvant endocrine therapy (AET) adherence in breast cancer survivors, according to a review published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2023 Category: Pharmaceuticals Source Type: news
Low Recurrence Seen With Omission of Radiation in Some Breast Cancer Cases
THURSDAY, Aug. 17, 2023 -- The incidence of local recurrence at five years is low among women aged at least 55 years with T1N0, grade 1 or 2, luminal A breast cancer who were treated with breast-conserving surgery and endocrine therapy without... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2023 Category: Pharmaceuticals Source Type: news
Higher Risk of Death With Endocrine Therapy Nonadherence Higher Risk of Death With Endocrine Therapy Nonadherence
Women with early-stage hormone receptor –positive breast cancer who do not adhere or persist with adjuvant endocrine therapy have a higher risk of relapse or mortality, a new analysis suggests.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Endocrine Therapy Plus Targeted Agents in MBC Endocrine Therapy Plus Targeted Agents in MBC
Endocrine therapy remains the mainstay of treatment in metastatic breast cancer. Dr Erica Mayer discusses adding targeted agents as clinicians strive to improve therapeutic options and efficacy.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Article Source Type: news
Ribociclib Forestalls Recurrence Also in Early Breast Cancer Ribociclib Forestalls Recurrence Also in Early Breast Cancer
The combination, known to be effective in metastatic disease, has now also been shown to reduce recurrence in earlier-stage disease when used in combination with endocrine therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 2, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
CDK4/6 Extends Reach Into Early-Stage Breast Cancer
(MedPage Today) -- CHICAGO -- Adding ribociclib (Kisqali) to adjuvant endocrine therapy significantly improved invasive disease-free survival (iDFS) in patients with early-stage, high-risk breast cancer and hormone receptor (HR)-positive/HER2... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 2, 2023 Category: Hematology Source Type: news
ASCO Backs Routine ESR1 Testing for Certain Breast Cancers
(MedPage Today) -- American Society of Clinical Oncology (ASCO) clinical practice guidelines now recommend routine testing for the emergence of ESR1 mutations at recurrence or progression on endocrine therapy -- with or without a CDK4/6 inhibitor... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - May 18, 2023 Category: OBGYN Source Type: news
Pausing Endocrine Therapy to Attempt Pregnancy Is Safe Pausing Endocrine Therapy to Attempt Pregnancy Is Safe
The POSITIVE trial provides strong evidence that women with HR-positive early breast cancer can safely interrupt endocrine therapy to try to become pregnant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 5, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Temporary Interruption of Endocrine Therapy for Breast Cancer Safe
THURSDAY, May 4, 2023 -- Among select women with previous hormone receptor-positive early breast cancer, there is no increase in the short-term risk for breast cancer events with temporary interruption of endocrine therapy to attempt pregnancy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 4, 2023 Category: Pharmaceuticals Source Type: news
Novartis gets positive result from breast-cancer drug trial
Novartis AG said Monday that a trial evaluating breast-cancer drug Kisqali met its primary endpoint during an interim analysis. The drug is shown to significantly reduce the risk of disease recurrence when used together with an endocrine therapy in patients with certain types of early breast…#novartisag #natalee #novartisnovn #novn (Source: Reuters: Health)
Source: Reuters: Health - March 27, 2023 Category: Consumer Health News Source Type: news
Is AI ready for managing patients with hip fractures?
Artificial intelligence (AI) algorithms can perform comparably to radiologist...Read more on AuntMinnie.comRelated Reading:
Fracture risk tool validated in men with prostate cancer
AI algorithm aids in classifying hip fractures on radiographs
Bone fractures are common after breast cancer endocrine therapy
New CPT code for radiology AI brings hope, but patience is needed
Using AI with x-ray improves hip fracture diagnosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 17, 2023 Category: Radiology Source Type: news
FDA Expands Indication for Use of Abemaciclib With Early, High-Risk Breast Cancer
FRIDAY, March 10, 2023 -- Abemaciclib (Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) is now approved for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2023 Category: Pharmaceuticals Source Type: news
FDA expands early breast cancer indication for abemaciclib with endocrine therapy
On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 6, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Broadens Indication for Verzenio (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
INDIANAPOLIS, March 3, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET),... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 3, 2023 Category: Drugs & Pharmacology Source Type: news
